AbbVie’s Aquipta & GSK’s Jesduvroq Move Closer To EU Market

AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.

Close-up of European Names on Maps
Two new drugs are set to be approved for use in Europe soon • Source: Shutterstock

The European Medicines Agency has recommended that two new drugs be approved for marketing in the EU – AbbVie’s Aquipta (atogepant monohydrate), for the prophylaxis of migraine, and GSK’s Jesduvroq (daprodustat), for treating adults with anemia associated with chronic kidney disease (CKD).

On the other hand, the agency said that Amylyx Pharmaceuticals’ Albrioza should not be approved for treating amyotrophic lateral sclerosis...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography